

Interim Phase 1 Results for SPY072, a Novel Half-Life Extended Monoclonal Antibody Targeting TL1A, Suggest A Potential for Q3M or Q6M Maintenance Dosing for Rheumatic Disease

Y. Vugmeyster<sup>1</sup>, S. Sloan<sup>1</sup>, JD Lu<sup>1</sup>, K.Hew<sup>1</sup>, P. Patel<sup>1</sup>, C. Sheldon<sup>1</sup>, D. Nguyen<sup>1</sup>, R. McLean<sup>1</sup>, M. Huyghe<sup>1</sup>, B. Connolly<sup>1</sup>, B. Wang<sup>2</sup>, M. Kennedy<sup>1</sup>, M. Rose<sup>1</sup>, E. Svejnoha<sup>1</sup>, J. Friedman<sup>1</sup>

<sup>1</sup>Spyre Therapeutics, Inc., Waltham, MA, United States; <sup>2</sup>Cinlanian, LLC, Ames, IA, United States



SPYRE  
THERAPEUTICS

2035

Background

- TL1A is a cytokine that activates T cell subtypes and fibroblast-like synoviocytes.
- Variants in the TL1A gene are associated with RA, PsA, and axSpA, and TL1A expression is increased in each.
- TL1A inhibition is effective in rodent arthritis models.
- SPY072 is a novel investigational, **extended half-life**, fully human IgG1 mAb that binds TL1A with **high affinity and specificity** and potently inhibits TL1A-mediated signaling.
- SPY072 is being studied in a Phase 1, single ascending dose clinical trial in healthy subjects (NCT06622070).
- SPY072 is also being studied for the treatment of RA, PsA, and axSpA in the **SKYWAY-RD Phase 2 basket study** (NCT07148414).

Methods

- Participants in the U.S. and Canada were randomized 3:1 to receive either SPY072 or placebo in SAD cohorts.
- Blood and safety information were collected for AE, PK, PD, and ADA assessment. All data shown are latest available as of 03 July 2025.
- SPY072 pharmacodynamics were measured using assays of serum soluble total and free TL1A.

Results

Table 1: Demographics and baseline characteristics

| Cohort     | N  | Age, years<br>Mean (SD) | Female<br>Percent | Weight, kg<br>Mean (SD) | BMI, kg/m <sup>2</sup><br>Mean (SD) |
|------------|----|-------------------------|-------------------|-------------------------|-------------------------------------|
| 100 mg SC  | 8  | 38 (12)                 | 50.0              | 77 (12)                 | 26 (2)                              |
| 300 mg SC  | 8  | 40 (11)                 | 87.5              | 71 (15)                 | 25 (3)                              |
| 300 mg IV  | 8  | 37 (8)                  | 62.5              | 72 (10)                 | 25 (2)                              |
| 1000 mg IV | 8  | 34 (10)                 | 62.5              | 68 (7)                  | 26 (2)                              |
| 1500 mg IV | 8  | 42 (9)                  | 75.0              | 67 (11)                 | 25 (2)                              |
| Pooled SAD | 40 | 38 (10)                 | 67.5              | 71 (12)                 | 25 (2)                              |

SD = standard deviation

- Demographics were well balanced across cohorts and baseline characteristics were consistent with expectations for a phase 1 study in healthy participants.
- With up to 211 days of follow-up, 1 subject (out of 40) discontinued due to physician decision.

SPY072 demonstrated a favorable safety profile

Table 2: Interim, blinded treatment-emergent adverse events (TEAEs)


| Cohort     | N  | Subjects with ≥ 1 TEAE | Subjects with ≥ 1 TESAE | Subjects with ≥ 1 treatment-related AE | Subjects with ≥ 1 grade 2 TEAE |
|------------|----|------------------------|-------------------------|--|--------------------------------|
| 100 mg SC  | 8  | 2 (25%)                | 0                       | 0                                      | 0                              |
| 300 mg SC  | 8  | 5 (63%)                | 0                       | 2 (25%)                                | 1 (13%)                        |
| 300 mg IV  | 8  | 5 (63%)                | 0                       | 0                                      | 1 (13%)                        |
| 1000 mg IV | 8  | 3 (38%)                | 0                       | 1 (13%)                                | 0                              |
| 1500 mg IV | 8  | 1 (13%)                | 0                       | 0                                      | 0                              |
| Pooled SAD | 40 | 16 (40%)               | 0                       | 3 (8%)*                                | 2 (5%)                         |

\* Treatment-related TEAEs of gastroenteritis, rash, abdominal pain, and non-cardiac chest tightness, all resolved.

- TEAEs were generally mild and unrelated to study drug.
- No serious TEAEs or dose-dependent trends were observed.

SPY072 demonstrated rapid and sustained target engagement

Figure 2: Free Soluble TL1A




Points are median values. Values below LLOQ of 8 pg/mL plotted as one-half of LLOQ. N: Placebo (2-10), 100 mg SC (5-6), 300 mg SC (6), 300 mg IV (4-6), 1000 mg IV (1-6), 1500 mg IV (6)

- Rapid and sustained reduction of **free soluble TL1A** was achieved up to 20 weeks of follow-up at the lowest dose.
- Rapid, dose-dependent, sustained increases of **total (free + bound) soluble TL1A** were observed up to 24 weeks of follow-up.

SPY072 PK profiles demonstrated half-life extension

Figure 1: SPY072 PK profiles



SC=subcutaneous; IV=intravenous. Error bars represent SD. Values below LLOQ (1 µg/mL) treated as missing for calculations of the mean.

- SPY072 exhibited a differentiated PK profile, with a half-life of > 3x compared to first generation anti-TL1As, supporting quarterly or twice annual SC maintenance dosing.
- ADA rates were comparable or lower than first generation anti-TL1As, with no observed impact on PK or PD.

Table 3: SPY072 PK parameters

| Dose       | N | T <sub>max</sub> (days)* | C <sub>max</sub> (µg/mL) <sup>§</sup> | AUC <sub>0-∞</sub> (µg·day/mL) <sup>§</sup> |
|------------|---|--------------------------|---------------------------------------|---|
| 100 mg SC  | 6 | 8.5                      | 10.9 (25.8)                           | 715 (17.7)                                  |
| 300 mg SC  | 6 | 12.0                     | 39.1 (28.8)                           | 3590 (38.3)                                 |
| 300 mg IV  | 6 | NR                       | 135 (15.4)                            | 5290 (17.1)                                 |
| 1000 mg IV | 6 | NR                       | 453 (11.0)                            | 16900 (38.8)                                |
| 1500 mg IV | 6 | NR                       | 584 (19.2)                            | NR  |

\* Median. <sup>§</sup> Mean (CV%). NR=not reported

Conclusions

- In a Phase 1 study of healthy participants, SPY072 was **well tolerated**
- SPY002 demonstrated extended half-life and target engagement
- These interim results support the **potential for the treatment of rheumatic disease with SPY072 with quarterly or twice annual dosing.**
- These data support clinical testing of SPY072 in the ongoing **SKYWAY-RD Phase 2 basket study in which SPY072 is being evaluated for the treatment of RA, PsA, and axSpA** (NCT07148414).

References

1. Yuan, Z. *et al.* Gene polymorphisms and serum levels of TL1A in patients with rheumatoid arthritis. J. Cell. Physiol. 234, 11760–11767 (2019).
2. Wang, N.-G. *et al.* Genetic analysis of TNFST15 variants in ankylosing spondylitis. Int. J. Clin. Exp. Pathol. 8, 15210–5 (2015).
3. Siegel, M. *et al.* ACR 2025 Poster 0050
4. Képiró, L. *et al.* Genetic risk and protective factors of TNFSF15 gene variants detected using single nucleotide polymorphisms in Hungarians with psoriasis and psoriatic arthritis. Hum. Immunol. 75, 159–162 (2014).
5. Bull, M. J. *et al.* The Death Receptor 3–TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. J. Exp. Med. 205, 2457–2464 (2008).
6. Balyan, R. *et al.* P633 First-in-Human Pharmacokinetic and Safety Study of an Anti-TL1A Antibody, TEV-48574, in Healthy Volunteers and Asthma Patients. Journal of Crohn's and Colitis i1206-i1207 (2024).
7. Banfield, C. *et al.* First-in-Human, Randomized Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of PF-06480605 in Healthy Subjects. Br J Clin Pharmacol. 86, 812-824 (2020).
8. Prometheus Biosciences Corporate Presentation, August 2022.

**Disclosures:** All Spyre Therapeutics, Inc. authors own equity in Spyre Therapeutics, Inc.. BW is an employee of Cinlanian, LLC.